Compare Heron Therapeutics Inc (HRTX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Procter & Gamble Co — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Procter & Gamble Co trades at $150.16 (market cap $343.34B). The key difference: Procter & Gamble Co is far larger — about 4637.2× Heron Therapeutics Inc's market cap, and Procter & Gamble Co pays a 2.95% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Procter & Gamble Co for 131 Days on average.
| HRTX | PG | |
|---|---|---|
Market Cap | $74.04M | $343.34B |
Volume | 3,668,095 | 8,662,344 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $167.18 |
52-Week Low | $0.27 | $138.10 |
Typical Hold Time | 35 Days | 131 Days |
Enterprise Value | $180.78M | $369.18B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $1.88. Strong fundamentals include $84.28B revenue, 18.44% net margin, and robust cash flow generation. Recent developments include a WNBA partnership and a dividend declaration of $1.09 payable in August 2026.
PG offers stable growth with premium valuation metrics (P/E 22.33, P/S 4.11) supported by strong brand equity and dividend consistency. Risks include premium valuation concerns amid modest growth outlook and competitive pressures. Analyst consensus is bullish with a $160.13 price target, though near-term upside may be limited given current price proximity to the lower target range.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
